Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma

Oncology (Switzerland)

Volumn 84, Issue 2, 2012, Pages 123-126

  Clark, James M ^a   Kelley, Benjamin ^a   Titze, Jill ^a   Fung, Henry ^b   MacIejewski, John ^b   Nathan, Sunita ^b   Rich, Elizabeth ^b   Basu, Sanjib ^b   Kaufman, Howard L ^a,c  

^a Department of General Surgery ^*  (United States)

^b Division of Hematology Oncology and Stem Cell Transplant   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

High dose interleukin 2; Immunotherapy; Melanoma; Renal cell carcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GERIATRIC PATIENT; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CARCINOMA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METABOLIC ACIDOSIS; METASTATIC MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OLIGURIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84870735938     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342764     Document Type: Article

References (11)

1. Lucas R, McMichael T, Smith W, Armstrong B: Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental Burden of Disease Series, World Healt h Orga nization 2006; 13.
2. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-2127.
3. Cho E, Adami HO, Lindblad P: Epidemiology of renal cell cancer. Hematol Oncol Clin North Am 2011; 25:651-665.
4. Howlader N, Noone AM, Krapcho M, Ney-man N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): SEER Ca ncer Statist ics Rev iew, 1975-2009 (Vintage 2009 Populations). Bethesda, MD, National Cancer Institute, 2011. http://seer.cancer.gov/csr/1975-2009-pops09/(accessed June 26, 2012).
5. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA: Correlation of NRAS mutations with clinical response to highdose IL-2 in patients wit h advanced melanoma. J Immunother 2012; 35: 66-72.
6. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA: Treatment of meta-static melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-5618.
7. George S, Pili R, Carducci MA, Kim JJ: Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011; 9: 1011-1018.
8. He X, Clarke SJ, McLachlan AJ: Clinical pharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriatr Res 2011; 2011:628670.
9. Aggarwal C, Langer CJ: Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsma ll cell lung ca ncer. Curr Opin Oncol 2012; 24: 130-136.
10. Zbar AP, Gravitz A, Audisio RA: Principles of surgical oncolog y in the elderly. Clin Geri-atr Med 2012; 28: 51-71.
11. Cesana GC, DeRaffele G, Cohen S, Morozie-wicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose in-terleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-1177.